首页> 外文期刊>DNA and Cell Biology >Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction
【24h】

Identification of a New Eight-Long Noncoding RNA Molecular Signature for Breast Cancer Survival Prediction

机译:鉴定乳腺癌存活预测的新八长的Nongoding RNA分子鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

Because of the phenotypic and molecular diversity, it is still difficult to predict breast cancer prognosis. This study aimed to develop and validate a multi-lncRNA (long noncoding RNA) signature to improve the survival prediction for breast cancer. Three hundred twenty-seven breast cancer patients from GSE20685 were used as a training set. GSE88770 including 117 patients and The Cancer Genome Atlas datasets including 1077 patients were used as 2 validation sets. Kaplan–Meier curve, the LASSO (least absolute shrinkage and selection operator) method, univariate and multivariate Cox analyses were applied to build a molecular model for predicting survival. Function analysis of this lncRNA signature was investigated. A novel eight-lncRNA molecular signature was first identified from multiple datasets. This signature classified patients into the high-risk and low-risk groups. Breast cancer in the high-risk group showed significantly worse survival than that in the low-risk group. Further multivariate Cox analysis revealed that this molecular signature was an independent prognostic factor for breast cancer in the training and validation sets. Furthermore, stratification analyses showed that this molecular signature was also used to classify patients into the low- and high-risk groups in patients with low or high T-stage, patients with or without lymph node metastasis, older or younger, estrogen receptor-positive or -negative, and progesterone receptor-positive or -negative patients. Our eight-lncRNA signature was a powerful tool in predicting prognosis in Luminal B breast cancer based on molecular subtype. This lncRNA signature involved in cell adhesion, apoptosis, cell differentiation, and immune regulation. Our study provided a reliable eight-lncRNA molecular signature for survival prediction of breast cancer, and this signature can stratify patients into the high- and low-risk groups. This molecular signature may help the selection of the suitable treatment strategies.
机译:由于表型和分子多样性,仍然难以预测乳腺癌预后。本研究旨在开发和验证多LNCRNA(长型NORCODING RNA)签名,以改善乳腺癌的存活预测。来自GSE20685的三百二十七名乳腺癌患者用作训练集。 GSE88770包括117名患者和癌症基因组地图集数据集,包括1077名患者用作2个验证集。 Kaplan-Meier曲线,套索(最小绝对收缩和选择操作员)方法,单变量和多变量COX分析施用于构建预测存活的分子模型。调查了这种LNCRNA签名的功能分析。首先从多个数据集识别新的八个LNCRNA分子签名。该签名分类为高风险和低风险群体。高风险组中的乳腺癌显着更差的存活率而不是低风险组。进一步的多变量COX分析显示,该分子签名是培训和验证集中乳腺癌的独立预后因素。此外,分层分析表明,该分子签名也用于将患者分类为低于或高T-阶段,患者或不含淋巴结转移,较大或更年轻的雌激素受体阳性患者的低风险群体或 - 中间,孕酮受体阳性或阴性患者。我们的八个LNCRNA签名是基于分子亚型预测Luminal B乳腺癌预后的强大工具。这种LNCRNA签名涉及细胞粘附,细胞凋亡,细胞分化和免疫调节。我们的研究为乳腺癌的存活预测提供了一种可靠的八个LNCRNA分子签名,这种签名可以将患者分为高风险群体。该分子签名可以帮助选择合适的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号